Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates.

Ko SY, Akahata W, Yang ES, Kong WP, Burke CW, Honnold SP, Nichols DK, Huang YS, Schieber GL, Carlton K, DaSilva L, Traina-Dorge V, Vanlandingham DL, Tsybovsky Y, Stephens T, Baxa U, Higgs S, Roy CJ, Glass PJ, Mascola JR, Nabel GJ, Rao SS.

Sci Transl Med. 2019 May 15;11(492). pii: eaav3113. doi: 10.1126/scitranslmed.aav3113.

PMID:
31092692
2.

Structural studies of Chikungunya virus maturation.

Yap ML, Klose T, Urakami A, Hasan SS, Akahata W, Rossmann MG.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13703-13707. doi: 10.1073/pnas.1713166114. Epub 2017 Dec 4.

3.

An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Urakami A, Ngwe Tun MM, Moi ML, Sakurai A, Ishikawa M, Kuno S, Ueno R, Morita K, Akahata W.

J Virol. 2017 Nov 14;91(23). pii: e01181-17. doi: 10.1128/JVI.01181-17. Print 2017 Dec 1.

4.

Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.

Urakami A, Sakurai A, Ishikawa M, Yap ML, Flores-Garcia Y, Haseda Y, Aoshi T, Zavala FP, Rossmann MG, Kuno S, Ueno R, Akahata W.

Clin Vaccine Immunol. 2017 Jul 5;24(7). pii: e00090-17. doi: 10.1128/CVI.00090-17. Print 2017 Jul.

5.

Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission.

Porta J, Mangala Prasad V, Wang CI, Akahata W, Ng LF, Rossmann MG.

J Virol. 2015 Nov 4;90(3):1169-77. doi: 10.1128/JVI.02364-15. Print 2016 Feb 1.

6.

Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE Jr, Diamond MS, Rossmann MG.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13898-903. doi: 10.1073/pnas.1515558112. Epub 2015 Oct 26.

7.

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.

Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE; VRC 311 Study Team.

Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14.

PMID:
25132507
8.

Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.

Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS.

PLoS Pathog. 2013;9(4):e1003312. doi: 10.1371/journal.ppat.1003312. Epub 2013 Apr 18.

9.

Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization.

Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, Diamond MS, Nabel GJ, Rossmann MG.

Elife. 2013 Apr 2;2:e00435. doi: 10.7554/eLife.00435.

10.
11.

A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.

Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ.

Nat Med. 2010 Mar;16(3):334-8. doi: 10.1038/nm.2105. Epub 2010 Jan 28.

12.

Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity.

Honda M, Wang R, Kong WP, Kanekiyo M, Akahata W, Xu L, Matsuo K, Natarajan K, Robinson H, Asher TE, Price DA, Douek DC, Margulies DH, Nabel GJ.

J Immunol. 2009 Aug 15;183(4):2425-34. doi: 10.4049/jimmunol.0900581. Epub 2009 Jul 20.

13.

Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis.

Ganesh L, Yoshimoto T, Moorthy NC, Akahata W, Boehm M, Nabel EG, Nabel GJ.

Mol Cell Biol. 2006 May;26(10):3864-74.

14.

Analysis of evolutionary conservation in CD1d molecules among primates.

Saito N, Takahashi M, Akahata W, Ido E, Hidaka C, Ibuki K, Miura T, Hayami M, Takahashi H.

Tissue Antigens. 2005 Dec;66(6):674-82.

PMID:
16305684
15.

DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles.

Horiuchi R, Akahata W, Kuwata T, Enose Y, Ido E, Suzuki H, Miyake A, Saito N, Ibuki K, Goto T, Miura T, Hayami M.

Vaccine. 2006 Apr 24;24(17):3677-85. Epub 2005 Jul 20.

PMID:
16085341
17.

DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles.

Akahata W, Ido E, Akiyama H, Uesaka H, Enose Y, Horiuchi R, Kuwata T, Goto T, Takahashi H, Hayami M.

J Gen Virol. 2003 Aug;84(Pt 8):2237-44.

PMID:
12867656
19.
20.

DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.

Akahata W, Ido E, Shimada T, Katsuyama K, Yamamoto H, Uesaka H, Ui M, Kuwata T, Takahashi H, Hayami M.

Virology. 2000 Sep 15;275(1):116-24.

21.

Sequential analysis of apoptosis induction in peripheral blood mononuclear cells and lymph nodes in the early phase of pathogenic and nonpathogenic SIVmac infection.

Iida T, Ichimura H, Ui M, Shimada T, Akahata W, Igarashi T, Kuwata T, Ido E, Yonehara S, Imanishi J, Hayami M.

AIDS Res Hum Retroviruses. 1999 May 20;15(8):721-9.

PMID:
10357468

Supplemental Content

Loading ...
Support Center